Indication
Treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Medicine details
- Medicine name:
- tafamidis (Vyndaqel)
- SMC ID:
- SMC2426
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Resubmission
- Publication due date:
- 13 December 2021
- SMC meeting date:
- 02 November 2021